Cadrenal Therapeutics
CVKD
9 hedge funds and large institutions have $165K invested in Cadrenal Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.56% less ownership
Funds ownership: 0.71% → 0.15% (-0.56%)
10% less funds holding
Funds holding: 10 → 9 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
84% less capital invested
Capital invested by funds: $1.04M → $165K (-$870K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$39.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.62K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$7.31K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$62 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$35 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$823K |
| 2 |
Renaissance Technologies
New York
|
-$40.9K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$12K |
| 4 |
VF
Virtu Financial
New York
|
-$3.53K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$602 |
CVKD Hedge Fund Activity: Q2 2024 in Review
9 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q2 2024, worth a combined $165K — down 84% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CVKD and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Avantax Planning Partners, adding an estimated $39.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $823K sold.
- 9 institutional investors held Cadrenal Therapeutics (CVKD) as of Q2 2024, down from 10 in Q1 2024.
- Funds reported $165K of Cadrenal Therapeutics stock for Q2 2024, down 84% quarter-over-quarter.
- 2 funds opened new Cadrenal Therapeutics positions in Q2 2024 and 3 closed out, a net change of -1 holder.
- The largest Cadrenal Therapeutics buyer in Q2 2024 was Avantax Planning Partners, an estimated $39.2K added.
- The largest Cadrenal Therapeutics seller in Q2 2024 was Armistice Capital, an estimated $823K sold.
Based on aggregated 13F filings for Q2 2024.